Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
Blum exercised stock options at $10.60 and sold at $76.76, capturing significant appreciation.
Cytokinetics CEO Robert Blum recently sold 7,500 shares of the company's stock, valued at $575,700, according to a recent SEC Form 4 filing. The transaction, which took place on August 10, 2026, saw the shares sold at a weighted average price of $76.76 per share, with a post-transaction market value of $77.49 per share. Cytokinetics, a clinical-stage biopharmaceutical company with a market capitalization of $10.6 billion, is developing innovative cardiac therapeutics using its proprietary muscle modulation platform.
The company has already achieved commercial success with MYQORZO and maintains a pipeline of muscle-targeted candidates aimed at addressing significant unmet medical needs in cardiology.
Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
